262 related articles for article (PubMed ID: 37430374)
1. Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria.
Zhao XN; Liu SX; Wang ZZ; Zhang S; You LL
Eur J Med Res; 2023 Jul; 28(1):230. PubMed ID: 37430374
[TBL] [Abstract][Full Text] [Related]
2. Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients.
Song J; Chen X; Zhou L; Yu W; Liu H; Yuan F
J Int Med Res; 2023 Oct; 51(10):3000605231204475. PubMed ID: 37843847
[TBL] [Abstract][Full Text] [Related]
3. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
4. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
5. Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study.
Zhang X; Jia R; Zheng Z; Jiang L; Xu Y; Raj A; Sun D
Eur J Med Res; 2023 Nov; 28(1):489. PubMed ID: 37936193
[TBL] [Abstract][Full Text] [Related]
6. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
Weir MR
Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.
Mima A; Horii Y
In Vivo; 2022; 36(4):1785-1789. PubMed ID: 35738640
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M
Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
[TBL] [Abstract][Full Text] [Related]
9. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis.
Zheng Q; Zhang P; Yang H; Geng Y; Tang J; Kang Y; Qi A; Li S
Heliyon; 2023 Apr; 9(4):e15310. PubMed ID: 37123954
[TBL] [Abstract][Full Text] [Related]
10. Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients on hemodialysis.
Yoshida S; Saito T; Shibagaki K; Hirao K; Yuza T; Tomosugi N; Honda H
Sci Rep; 2023 Feb; 13(1):3181. PubMed ID: 36823243
[TBL] [Abstract][Full Text] [Related]
11. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
[TBL] [Abstract][Full Text] [Related]
12. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial.
Lim JH; Jeon Y; Yook JM; Choi SY; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Cho JH
Sci Rep; 2020 Sep; 10(1):16062. PubMed ID: 32994531
[TBL] [Abstract][Full Text] [Related]
13. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of switching treatment from high dose of darbepoetin to lower dose of roxadustat in Japanese hemodialysis patients.
Kanda R; Kubo A; Seki T; Urita A; Sekiuchi M; Tomino Y
Ther Apher Dial; 2022 Apr; 26(2):357-361. PubMed ID: 34333847
[TBL] [Abstract][Full Text] [Related]
15. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
Belo L; Rocha S; Valente MJ; Coimbra S; Catarino C; Bronze-da-Rocha E; Rocha-Pereira P; do Sameiro-Faria M; Oliveira JG; Madureira J; Fernandes JC; Miranda V; Santos-Silva A
Ren Fail; 2019 Nov; 41(1):662-672. PubMed ID: 31296086
[No Abstract] [Full Text] [Related]
16. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
Csiky B; Schömig M; Esposito C; Barratt J; Reusch M; Valluri U; Sulowicz W
Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926
[TBL] [Abstract][Full Text] [Related]
17. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Pergola PE; Devalaraja M; Fishbane S; Chonchol M; Mathur VS; Smith MT; Lo L; Herzog K; Kakkar R; Davidson MH
J Am Soc Nephrol; 2021 Jan; 32(1):211-222. PubMed ID: 33272965
[TBL] [Abstract][Full Text] [Related]
18. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
Akizawa T; Ueno M; Shiga T; Reusch M
Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
[TBL] [Abstract][Full Text] [Related]
19. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
[TBL] [Abstract][Full Text] [Related]
20. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
